CD274 and non-small cell lung carcinoma: It also revealed that the Ventana SP142 assay’s analytical sensitivity was significantly lower than the three other FDA-approved PD-L1 assays in NSCLC and some other cancers (22C3 pharmDx, 28-8 pharmDx, and Ventana SP263 assays).